DexCom, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.66B | $4.03B | $3.62B | $2.91B | $2.45B | $1.93B | $1.48B | $1.03B |
| Cost of Revenue | $1.86B | $1.59B | $1.33B | $1.03B | $768.0M | $646.6M | $544.5M | $367.7M |
| Gross Profit | $2.80B | $2.44B | $2.29B | $1.88B | $1.68B | $1.28B | $931.5M | $663.9M |
| Gross Margin | 60.1% | 60.5% | 63.2% | 64.7% | 68.6% | 66.4% | 63.1% | 64.4% |
| Operating Expenses | ||||||||
| Research & Development | $599.1M | $552.4M | $505.8M | $484.2M | $517.1M | $359.9M | $273.5M | $199.7M |
| SG&A Expense | $1.29B | $1.29B | $1.19B | $1.01B | $810.5M | $618.2M | $515.7M | $432.8M |
| Operating Income | $911.8M | $600.0M | $597.7M | $391.2M | $265.8M | $299.5M | $142.3M | $-186.3M |
| Operating Margin | 19.6% | 14.9% | 16.5% | 13.4% | 10.9% | 15.5% | 9.6% | -18.1% |
| Interest Expense | $14.3M | $14.9M | $20.3M | $18.6M | $18.8M | $17.7M | $60.3M | $22.7M |
| Pretax Income | $1.09B | $709.0M | $710.4M | $390.8M | $256.8M | $297.9M | $104.2M | $-126.5M |
| Income Tax Expense | $252.1M | $132.8M | $168.9M | $49.6M | $39.9M | $-251.8M | $3.1M | $600.0K |
| Net Income | $836.3M | $576.2M | $541.5M | $341.2M | $216.9M | $549.7M | $101.1M | $-127.1M |
| Net Margin | 17.9% | 14.3% | 14.9% | 11.7% | 8.9% | 28.5% | 6.8% | -12.3% |
| EPS (Basic) | $2.14 | $1.46 | $1.40 | $0.88 | $0.56 | $1.46 | $0.22 | $-0.29 |
| EPS (Diluted) | $2.09 | $1.42 | $1.30 | $0.82 | $0.53 | $1.33 | $0.22 | $-0.29 |
| Shares Outstanding (Basic) | 390.2M | 393.6M | 386.0M | 389.4M | 386.9M | 377.5M | 455.5M | 441.0M |
| Shares Outstanding (Diluted) | 405.5M | 412.7M | 425.5M | 427.5M | 428.8M | 420.4M | 461.5M | 441.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |